Cardio Diagnostics Holdings Inc - CDIO STOCK NEWS

Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO) has published groundbreaking research in the journal Genes, revealing the potential for reversing epigenetic changes associated with coronary heart disease (CHD) through smoking cessation. The study examined the impact of smoking cessation on DNA methylation sites assessed by Cardio Diagnostics' PrecisionCHD test. Participants who quit smoking showed increased methylation at five of the six sites, indicating more normal regulation of disease-related genes. This discovery suggests that methylation-based approaches could be used to evaluate the effectiveness of CHD interventions.

Cardio Diagnostics Holdings, Inc announces partnership with Connect Clinic to provide heart disease initiatives for self-insured employers in the Midwest/South Central regions. The collaboration aims to make advanced precision heart disease technologies more accessible and reduce the burden of heart disease on the workforce.

Cardio Diagnostics Holdings, Inc has announced the availability of its CardioInnovate360TM research-use-only solution for biopharmaceutical companies in the cardiovascular disease market. The global cardiovascular drugs market is expected to reach over $231 billion by 2030. The solution has the potential to provide a new revenue stream for Cardio Diagnostics and establish a footprint in a new market.

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) announced that its PrecisionCHD™ test received the Future Digital Award for ‘Best Digital Diagnostics Solution’ from Juniper Research. This award recognizes companies delivering impactful digital health solutions. PrecisionCHD is the second test utilizing Cardio Diagnostics' proprietary AI-driven Integrated Epigenetic-Genetic Engine, which combines epigenetic and genetic biomarkers to detect coronary heart disease (CHD) with over 75% sensitivity. The test is designed to be accessible in various healthcare settings, contributing to democratizing cardiovascular care. CEO Meesha Dogan expressed dedication to innovation and improving patient outcomes. The company aims to develop additional tests for other cardiovascular diseases, enhancing early detection and personalized care.

Cardio Diagnostics Holdings, Inc (NASDAQ: CDIO) is participating in the 22nd Annual Association of Home Office Underwriters (AHOU) Conference from April 16-19, 2023, at The Diplomat Beach Resort, Hollywood, Florida. The conference addresses innovations in life insurance underwriting, especially relating to heart disease, which significantly impacts insurance payouts.

Cardio Diagnostics is a leader in precision cardiovascular medicine, utilizing epigenetics and AI for early detection of cardiovascular diseases, including coronary heart disease (CHD). They will showcase solutions like Epi+Gen CHD and PrecisionCHD, alongside their Actionable Clinical Intelligence™ platform. The CEO, Meesha Dogan, emphasized their commitment to integrating advanced technology in underwriting processes to reduce heart disease-related claims.

Cardio Diagnostics (Nasdaq: CDIO) has announced a strategic engagement with Lifespan.io to enhance awareness and education around heart disease prevention and longevity. This collaboration includes attendance at Lifespan.io's conference, research articles, and discussions on cardiovascular health, epigenetics, and AI-driven diagnostics. Lifespan.io, a nonprofit organization, focuses on extending healthy human lifespan through research and education. The partnership aims to empower individuals to adopt healthier heart practices. Initial resources will be launched in April, with further initiatives planned for the future.